EUVIMEDEUVIMED entdecken
Crossref

Automated Synthesis and Preclinical Evaluation of Optimized Integrin α6-Targeted Positron Emission Tomography Imaging of Pancreatic Cancer

Liping Chen iD, Haitian Fu, Huihui He, Kequan Lou, Qingbo Li, Jiacong Ye, Guokai Feng iD, Chunjing Yu iD

Molecular Pharmaceutics · 2023

DOI: 10.1021/acs.molpharmaceut.3c00321 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2023. Verfasst von Liping Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Affiliated Hospital of Jiangnan University, 1000 Hefeng Road, Binhu District, Wuxi 214062, P.R. China. Hauptthemen laut MEDLINE: Heterocyclic Compounds, 1-Ring, Pancreatic Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 19 Literaturangaben. Gefördert von: Jiangnan University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Integrin α6 has been considered a promising biomarker, is overexpressed in many tumors, and plays a vital role in tumor formation, recurrence, and metastasis. In this study, we identified a novel high-affinity integrin α6-targeted peptide named RD2 (Arg-Trp-Tyr-Asp-PEG4)2-Lys-Lys and developed a 18F-radiolabeled peptide tracer ([18F]-AlF-NOTA-RD2) and evaluated its potential application in positron emission tomography (PET) imaging of pancreatic cancer. [18F]-AlF-NOTA-RD2 was produced using GMP (Good Manufacturing Practice of Medical Products)-compliant automatic radiosynthesis on a single GE FASTLab2 cassette-type synthesis module. The stability of [18F]-AlF-NOTA-RD2 was analyzed in phosphate-buffered saline (PBS) and fetal bovine serum (FBS). The cell uptake assay of the tracer was assessed using PANC-1 cells. In addition, small-animal PET imaging and biodistribution studies of [18F]-AlF-NOTA-RD2 were performed in pancreatic cancer subcutaneous tumor-bearing mice. The PET tracer [18F]-AlF-NOTA-RD2 was obtained with a radiochemical yield of 23.7 ± 4.7%, radiochemical purity of >99%, and molar activity of 165.7 ± 59.1 GBq/μmol. [18F]-AlF-NOTA-RD2 exhibited good in vitro stability in PBS and FBS. LogP octanol water value for the tracer was -2.28 ± 0.05 (n = 3). The binding affinity of RD2 to the integrin α6 protein (Kd = 0.13 ± 3.65 μM, n = 3) was significantly higher than that of the RWY (CRWYDENAC) (Kd = 6.97 ± 1.44 μM, n = 3). Small-animal PET imaging and biodistribution also revealed that [18F]-AlF-NOTA-RD2 displayed rapid and good tumor uptake and lower liver background uptake in PANC-1 tumor-bearing mice. [18F]-AlF-NOTA-RD2 showed significant radioactivity accumulation in tumors and was successfully blocked by NOTA-RD2. Compared with [18F]-FDG, [18F]-AlF-NOTA-RD2 PET imaging and biodistribution studies in PANC-1 xenograft tumor-bearing mice confirmed a good tumor-to-muscle ratio (8.69 ± 2.03 vs 1.41 ± 0.23, respectively) at 0.5 h and (2.99 ± 3.02 vs 1.43 ± 0.17, respectively) at 1 h post injection. Autoradiography of human pancreatic cancer tumor tissues further confirmed high accumulation of [18F]-AlF-NOTA-RD2. In summary, we developed an optimized integrin α6-targeted imaging tracer and obtained high radioactivity products with a cassette-type synthesis module; moreover, the tracer exhibited good binding affinity with integrin α6 and good target specificity for PANC-1 cells in xenograft pancreatic tumor-bearing mice, demonstrating its promising application as a noninvasive PET radiotracer of integrin α6 expression in pancreatic cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heterocyclic Compounds, 1-RingPancreatic NeoplasmsHumansMiceAnimalsIntegrin alpha6Tissue DistributionFluorine RadioisotopesCell Line, TumorPositron-Emission TomographyPeptidesFluorodeoxyglucose F18

Stichwörter der Autor:innen

integrin α6molecular imagingpancreatic cancerpositron emission computed tomography

Substanzen

Heterocyclic Compounds, 1-RingIntegrin alpha6Fluorine RadioisotopesPeptidesFluorodeoxyglucose F18

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Affiliated Hospital of Jiangnan University, 1000 Hefeng Road, Binhu District, Wuxi 214062, P.R. China.
  • Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 Dongfeng Road East, Guangzhou 510060, P.R. China.

ORCID-Profile: Liping Chen, Guokai Feng, Chunjing Yu

Förderung

  • Jiangnan University

Zitieren

APA

Chen, L., Fu, H., He, H., Lou, K., Li, Q., Ye, J., Feng, G., & Yu, C. (2023). Automated Synthesis and Preclinical Evaluation of Optimized Integrin α6-Targeted Positron Emission Tomography Imaging of Pancreatic Cancer. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.3c00321

Vancouver

Chen L, Fu H, He H, Lou K, Li Q, Ye J, et al. Automated Synthesis and Preclinical Evaluation of Optimized Integrin α6-Targeted Positron Emission Tomography Imaging of Pancreatic Cancer. Molecular Pharmaceutics. 2023. doi:10.1021/acs.molpharmaceut.3c00321

BibTeX
@article{Chen2023,
  author = {Chen, Liping and Fu, Haitian and He, Huihui and Lou, Kequan and Li, Qingbo and Ye, Jiacong and Feng, Guokai and Yu, Chunjing},
  title = {Automated Synthesis and Preclinical Evaluation of Optimized Integrin α6-Targeted Positron Emission Tomography Imaging of Pancreatic Cancer},
  journal = {Molecular Pharmaceutics},
  year = {2023},
  doi = {10.1021/acs.molpharmaceut.3c00321}
}
Kostenlos starten →